Torl Biotherapeutics, Llc
Clinical trials sponsored by Torl Biotherapeutics, Llc, explained in plain language.
-
New drug combo aims to shrink ovarian tumors before surgery
Disease control Recruiting nowThis study tests a new drug called TORL-1-23 given with chemotherapy before surgery for women with advanced ovarian cancer. The goal is to see if the combination is safe and helps shrink tumors more effectively. About 60 women with stage III or IV ovarian, fallopian tube, or peri…
Phase: PHASE1, PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New drug TORL-1-23 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurab…
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
New hope for hard-to-treat ovarian cancer: targeted drug enters phase 2 trial
Disease control Recruiting nowThis study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…
Phase: PHASE2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated May 26, 2026 08:56 UTC